Clinical trials
Conversion Therapy clinical trials
Below are recruiting conversion therapy clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07501351RecruitingPhase 2
Comparing two therapies for advanced liver cancer after first treatment fails
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
Guangzhou, GuangdongAges 18–75 - NCT05220982Recruiting
Voice therapy help through a phone app and telepractice
This study tests a voice-therapy program delivered through live online sessions (telepractice) plus a smartphone or tablet app. It may help people improve their voice use safely and effectively, especially teachers who have voice complaints.
West Chester, PennsylvaniaAges 18 years+ - NCT07560488RecruitingPhase 2
Immunotherapy and Chemotherapy Combination for Advanced Liver Cancer
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06405321Recruiting
Initial therapy before surgery for liver cancer
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
Nanning, ChinaAges 18–75 - NCT06949111RecruitingPhase 2
Combining radiation and chemo to make colon cancer removable
This trial tests whether giving radiation therapy along with standard chemotherapy before surgery can help shrink advanced colon cancer that has grown through the bowel wall but hasn't spread to other organs. It is for a specific type of colon cancer called pMMR/MSS.
Shijiazhuang, HebeiAges 18 years+ - NCT05837052RecruitingPhase 2
Serplulimab plus chemo after initial treatment for lung cancer
This Phase 2 study looks at how safe and effective serplulimab (an immune medicine) combined with chemotherapy is when used as a “conversion” plan—first shrinking lung cancer, then trying to remove the main tumor with surgery. It may help some people who are not initially good candidates for surgery or focused radiation to become eligible after treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06709859RecruitingPhase 2
Afatinib plus chemo for unresectable stage III lung cancer
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
Jinan, ShangdongAges 18 years+ - NCT06187961RecruitingPhase 2
Combination therapy for liver cancer that cannot be removed with surgery
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Wuhan, HubeiAges 18 years+ - NCT07757165RecruitingPhase 2
Surgery after drug treatment for advanced stomach cancer
This trial is for people with advanced stomach cancer that has shrunk after initial chemotherapy or targeted therapy. It compares whether adding surgery to continued medical treatment is better than staying on medical treatment alone, with the goal of improving outcomes.
ShanghaiAges 18–75 - NCT06215651RecruitingPhase 2
Testing cadonilimab and lenvatinib before liver cancer surgery
This study tests whether a combination of two drugs (cadonilimab and lenvatinib) can shrink liver cancer enough to make it removable by surgery for people whose cancer was previously too advanced for surgery. You may qualify if your cancer hasn't spread far, you haven't had treatment before, and your liver is still working fairly well.
Beijing, Beijing MunicipalityAges 18–75 - NCT07353684RecruitingPhase 2
Adebrelimab plus apatinib with chemo for gastric cancer
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Beijing, Beijing MunicipalityAges 18–75 - NCT07549100Recruiting
Tislelizumab plus chemotherapy for advanced esophageal cancer
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
Jinan, ShandongAges 18–75 - NCT07607873Recruiting
Transplant vs surgery after chemo for liver-only colorectal cancer
This trial compares liver transplant versus liver surgery for people whose colorectal cancer has spread only to the liver and cannot be removed initially. You would first receive chemotherapy to shrink the tumors, and if they become removable, you may be randomly assigned to have a liver transplant or standard liver surgery.
MilanAges 18 years+ - NCT07438106RecruitingPhase 2
HRS-4642 with chemo to shrink pancreatic cancer before surgery
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
NanjingAges 18–75 - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT04047953Recruiting
Chemo for stomach cancer to make tumors easier to remove
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
Beijing, Beijing MunicipalityAges 18–75 - NCT04687631RecruitingPhase 3
Study drug for colorectal cancer that spread to the liver
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT06091423RecruitingPhase 2
XELOX plus fruquintinib and sintilimab for stomach cancer with liver or lymph node spread
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
NanjinAges 18–75 - NCT06382103Recruiting
Liver cancer study after surgery or pre-surgery therapy
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
ShanghaiAges Any age - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT06571396Recruiting
Surgery risks after immunotherapy for liver cancer
This study looks at the risks of surgery in people with liver cancer who received immunotherapy before or instead of surgery. It aims to understand how safe and effective this approach is.
Jinan, ShandongAges 18 years+
Hear when a new Conversion Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for conversion therapy?
- Yes. Clin2 currently lists 32 recruiting conversion therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a conversion therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a conversion therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.